Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2010 Ottobre;51(5) > The Journal of Cardiovascular Surgery 2010 Ottobre;51(5):747-54

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

REVIEWS  RECENT ADVANCES IN RENAL ARTERY STENTING


The Journal of Cardiovascular Surgery 2010 Ottobre;51(5):747-54

lingua: Inglese

Efficacy of embolic protection devices in renal artery stenting

Campbell J. E. 1, Stone P. A. 1, Bates M. C. 1,2

1 Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Charleston Division, Charleston, WV, USA
2 Vascular Center of Excellence, Charleston Area Medical Center, Charleston, WV, USA


PDF  


The efficacy of embolic protection devices (EPDs) have been studied extensively in coronary saphenous vein grafts and extra cranial cerebrovascular disease. Recent ex-vivo and in-vivo renal artery stenting studies suggest atheroembolism is not unique to the coronary and cerebrovascular domain and it seems intuitive, renal EPDs may be beneficial. In an attempt to better understand the current objective evidence regarding renal protection efficacy we systematically reviewed the contemporary literature and summarize the findings herein. There is increasing observational data suggesting the use of embolic protection devices decrease the risk of continued decline in renal function after renal artery stenting. There is also prospective randomized data to suggest that the use of adjuvant IIb/IIIa glycoprotein inhibitor and embolic protection has synergistic benefit, but this is a very small series. However, there are currently no well controlled prospective trials to conclude the added risk and expense of renal protection is countered by proven clinical benefit. Based on the literature compiled in this manuscript we do believe EPDs should be considered in some high-risk patients.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

jcampbell9974@yahoo.com